Omalizumab for treatment of ABPA exacerbations in CF patients.
Lebecque
Patrick
P
Leonard
Anissa
A
Pilette
Charles
C
D000293:Adolescent; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000150:complications* / Q000188:drug therapy*; D003550:Cystic Fibrosis / Q000150:complications*; D006801:Humans; D000069444:Omalizumab
D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab